ARWR - Arrowhead Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ARWR is currently covered by 11 analysts with an average price target of $36.41. This is a potential upside of $20.35 (126.71%) from yesterday's end of day stock price of $16.06.

Arrowhead Pharmaceuticals's activity chart (see below) currently has 200 price targets and 179 ratings on display. The stock rating distribution of ARWR is 83.33% BUY and 16.67% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 66.83% with an average time for these price targets to be met of 256.95 days.

Highest price target for ARWR is $80, Lowest price target is $26, average price target is $44.22.

Most recent stock forecast was given by PATRICK TRUCCHIO from HC WAINWRIGHT on 20-May-2025. First documented stock forecast 18-Dec-2013.

Currently out of the existing stock ratings of ARWR, 35 are a BUY (83.33%), 7 are a HOLD (16.67%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$80

$63.94 (398.13%)

$80

2 months 20 days ago
(20-May-2025)

0/22 (0%)

$63.71 (391.10%)

Buy

$60

$43.94 (273.60%)

$60

2 months 27 days ago
(13-May-2025)

4/20 (20%)

$44.72 (292.67%)

193

Buy

$38

$21.94 (136.61%)

$55

5 months 26 days ago
(14-Feb-2025)

8/16 (50%)

$18.89 (98.85%)

135

Buy

$42

$25.94 (161.52%)

$42

5 months 29 days ago
(11-Feb-2025)

2/10 (20%)

$23.11 (122.34%)

100

Buy

$45

$28.94 (180.20%)

$62

8 months 13 days ago
(27-Nov-2024)

22/36 (61.11%)

$18.85 (72.08%)

154

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ARWR (Arrowhead Pharmaceuticals) average time for price targets to be met?

On average it took 256.95 days on average for the stock forecasts to be realized with a an average price target met ratio 66.83

Which analyst has the current highest performing score on ARWR (Arrowhead Pharmaceuticals) with a proven track record?

LUCA ISSI

Which analyst has the most public recommendations on ARWR (Arrowhead Pharmaceuticals)?

Luca Issi works at RBC and has 10 price targets and 6 ratings on ARWR

Which analyst is the currently most bullish on ARWR (Arrowhead Pharmaceuticals)?

Esther Rajavelu with highest potential upside - $75.13

Which analyst is the currently most reserved on ARWR (Arrowhead Pharmaceuticals)?

Alethia Young with lowest potential downside - -$0

Arrowhead Pharmaceuticals in the News

Arrowhead Pharma stock price target lowered to $21 at Leerink Partners

Investing.com – Leerink Partners has lowered its price target on Arrowhead Pharmaceuticals (NASDAQ:ARWR) to $21.00 from $22.00 while maintaining a Market Perform rating following the company’s fiscal third-quarter 2025 results. The stock, currently trading at $16.06, remains below analyst consensus targets ranging from $17 to $80. According to InvestingPro analysis, the company appears slightly undervalued...

ARWR: Countdown to Nov. 18, 2025 PDUFA for Plozasiran for FCS…

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Countdown Begins to November 18, 2025 PDUFA for Plozasiran Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is developing plozasiran for the treatment of familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (sHTG). The company has filed a new drug application (NDA) with the U.S. Food and...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?